Paper35936699
The Combination of AFP and "Up-To-Seven" Criteria May Be a Better Strategy for Liver Transplantation in Chinese Cirrhotic HCC Patients.
Zhang DL and 10 others. Front Oncol, 2022. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. The Combination of AFP and "Up-To-Seven" Criteria May Be a Better Strategy for Liver Transplantation in Chinese Cirrhotic HCC Patients. Papers, record 35936699. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35936699
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The Combination of AFP and "Up-To-Seven" Criteria May Be a Better Strategy for Liver Transplantation in Chinese Cirrhotic HCC Patients.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References45
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 11391528 | Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. | Hepatology | 2001 | https://conductscience.org/library/papers/11391528 | PubMed |
| 2 | 23995766 | Hangzhou criteria for liver transplantation in hepatocellular carcinoma: a single-center experience. | Eur J Gastroenterol Hepatol | 2014 | https://conductscience.org/library/papers/23995766 | PubMed |
| 3 | 35002724 | Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/35002724 | PubMed |
| 4 | 28989060 | Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. | Gastroenterology | 2018 | https://conductscience.org/library/papers/28989060 | PubMed |
| 5 | 35550167 | Epigenetic regulation of the DNMT1/MT1G/KLF4/CA9 axis synergises the anticancer effects of sorafenib in hepatocellular carcinoma. | Pharmacol Res | 2022 | https://conductscience.org/library/papers/35550167 | PubMed |
| 6 | 31850994 | Locoregional Therapy, Pathologic Response, and HCC Recurrence After Liver Transplantation: Highlighting Success and Looking Toward the Future. | Ann Surg | 2020 | https://conductscience.org/library/papers/31850994 | PubMed |
| 7 | 34768358 | The Combination of Albumin-Bilirubin Score and Prothrombin Time Is a Useful Tool for Predicting Liver Dysfunction after Transcatheter Arterial Chemoembolization in Child-Pugh Class A Patients with Hepatocellular Carcinoma within Up-to-Seven Criteria. | J Clin Med | 2021 | https://conductscience.org/library/papers/34768358 | PubMed |
| 8 | 28859222 | Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis. | Hepatology | 2018 | https://conductscience.org/library/papers/28859222 | PubMed |
| 9 | 8594428 | Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. | N Engl J Med | 1996 | https://conductscience.org/library/papers/8594428 | PubMed |
| 10 | 30166858 | Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions. | World J Gastroenterol | 2018 | https://conductscience.org/library/papers/30166858 | PubMed |
| 11 | 33995073 | Dihydrotanshinone Inhibits Hepatocellular Carcinoma by Suppressing the JAK2/STAT3 Pathway. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/33995073 | PubMed |
| 12 | 34722189 | Hepatocellular Carcinoma and the Role of Liver Transplantation: A Review. | J Clin Transl Hepatol | 2021 | https://conductscience.org/library/papers/34722189 | PubMed |
| 13 | 34513717 | Novel Microcrystal Formulations of Sorafenib Facilitate a Long-Acting Antitumor Effect and Relieve Treatment Side Effects as Observed With Fundus Microcirculation Imaging. | Front Oncol | 2021 | https://conductscience.org/library/papers/34513717 | PubMed |
| 14 | 35605812 | Demethylzeylasteral targets lactate by inhibiting histone lactylation to suppress the tumorigenicity of liver cancer stem cells. | Pharmacol Res | 2022 | https://conductscience.org/library/papers/35605812 | PubMed |
| 15 | 28983565 | The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. | JAMA Oncol | 2017 | https://conductscience.org/library/papers/28983565 | PubMed |
| 16 | 22432733 | Systematic review: the role of liver transplantation in the management of hepatocellular carcinoma. | Aliment Pharmacol Ther | 2012 | https://conductscience.org/library/papers/22432733 | PubMed |
| 17 | 31774468 | Long-term Effects of Repeat Hepatectomy vs Percutaneous Radiofrequency Ablation Among Patients With Recurrent Hepatocellular Carcinoma: A Randomized Clinical Trial. | JAMA Oncol | 2020 | https://conductscience.org/library/papers/31774468 | PubMed |
| 18 | 31054040 | Prognostic Value and Prediction of Extratumoral Microvascular Invasion for Hepatocellular Carcinoma. | Ann Surg Oncol | 2019 | https://conductscience.org/library/papers/31054040 | PubMed |
| 19 | 31511501 | SREBP-1 inhibitor Betulin enhances the antitumor effect of Sorafenib on hepatocellular carcinoma via restricting cellular glycolytic activity. | Cell Death Dis | 2019 | https://conductscience.org/library/papers/31511501 | PubMed |
| 20 | 32801748 | Novel mTOR Inhibitor Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeting Agents. | Onco Targets Ther | 2020 | https://conductscience.org/library/papers/32801748 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42394399 | Review Article: Biomarkers in Liver Transplantation for Hepatocellular Carcinoma: Towards Precision Medicine. | Aliment Pharmacol Ther | 2026 | https://conductscience.org/library/papers/42394399 | PubMed |
| 41312914 | Prognostic Significance of Up-to-Seven Criteria Versus Milan Criteria for Hepatocellular Carcinoma Patients Undergoing Resection or Locoregional Therapy: A Systematic Review and Meta-Analysis. | Asian Pac J Cancer Prev | 2025 | https://conductscience.org/library/papers/41312914 | PubMed |
| 38927509 | Liver Transplantation for Hepatocarcinoma: Results over Two Decades of a Transplantation Programme and Analysis of Factors Associated with Recurrence. | Biomedicines | 2024 | https://conductscience.org/library/papers/38927509 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AFP | 174 | PubTator's text mining | https://conductscience.org/library/genes/174 | NCBI Gene |
| TENM1 | 10178 | PubTator's text mining | https://conductscience.org/library/genes/10178 | NCBI Gene |
| ZHX2 | 22882 | PubTator's text mining | https://conductscience.org/library/genes/22882 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35936699
GET https://conductscience.org/api/papers/v1/35936699/references?page=2